Elucidata’s Liver OmixAtlas, the largest repository of ML-ready liver tissue-derived biomedical molecular data, aims to address these issues and empower scientists to focus on insight discovery. In this video, our CEO, Abhishek Jha, and Lead Scientist, Shefali Lathwal, elaborate on how Liver OmixAtlas can help accelerate therapeutic asset discovery for liver-associated diseases.
Elucidata’s Liver OmixAtlas, the largest repository of ML-ready liver tissue-derived biomedical molecular data, aims to address these issues and empower scientists to focus on insight discovery. In this video, our CEO, Abhishek Jha, and Lead Scientist, Shefali Lathwal, elaborate on how Liver OmixAtlas can help accelerate therapeutic asset discovery for liver-associated diseases.
Scaling clinico-genomic data integration: Large pharmaceutical organizations working with external data providers used Polly to build interoperable clinico-genomic data products 6x faster.
Although purchased datasets are often labeled as "clean," they still lack interoperability—Polly's pipelines bridge this gap with robust integration and harmonization.
Information Retrieval: Drug safety monitoring teams used Polly's Knowledge Graph powered co-scientist to conversationally retrieve the right cohorts & assess drug response—cutting discovery time by 70%.
If you’re working with complex biological data, you may be asking:
Can generative AI truly assist in scientific reasoning, not just data analysis?
What does it mean for hypothesis generation, literature review, or even designing experiments?
Could this accelerate—not replace—my discovery pipeline?
Whether you're skeptical, curious, or already experimenting with AI in your lab—this is a session designed to ground your understanding in evidence, not speculation.